Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study evaluated the safety and performance of the Guardian™ continuous glucose monitoring (CGM) system in children and adolescents with type 1 diabetes (T1D). MATERIALS AND METHODS: Subjects 2-18 years of age (mean ± standard deviation [SD] 13.1 ± 3.9 years) with T1D and duration of diagnosis ≥1 year were enrolled at 11 sites in the United States and wore two Guardian Sensor 3 sensors in the abdomen and/or buttock. Sensors were connected to a transmitter paired with either a Guardian Connect system (i.e., mobile device with software application allowing display of sensor glucose [SG] values) or a Guardian Link 3 transmitter used as a Glucose Sensor Recorder (GSR). There were 145 participants who underwent a 6-h in-clinic frequent sample testing (FST) on day 1 (n = 54), day 3 (n = 48), or day 7 (n = 43) postsensor insertion. During FST, SG values were compared with a Yellow Springs Instrument (YSI) plasma reference every 5-15 min (n = 124, 7-18 years of age; n = 2, 2-6 years of age), or to a self-monitoring of blood glucose (SMBG) reference every 5-30 min (n = 19, 2-6 years of age). RESULTS: The overall mean absolute relative difference (ARD ± SD) between SG and reference values (YSI or SMBG) when calibrating approximately every 12 h, was 10.9% ± 10.7% (3102 paired points) for sensors communicating with the Guardian Connect system and 11.1% ± 10.6% (2624 paired points) for sensors connected to the GSR. The overall percentage of SG values within ±20% of reference values >80 mg/dL or within 20 mg/dL of reference values ≤80 mg/dL was 87.8% for the Guardian Connect system and 86.7% for the GSR, respectively. There was one device-related adverse event of contact dermatitis, but no serious device-related adverse events. CONCLUSIONS: The Guardian CGM system demonstrated good accuracy in children and adolescents. These findings support its use in sensor-integrated insulin pump platforms, as well as a standalone technology, for managing diabetes in pediatric populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“18,21 Nevertheless, improved glycemic control and clinical outcomes have been observed with consistent CGM use of at least 4.5 days/week 22 or 70% of the time, 8 in youth, as well as adults.”
InfluentialSelf-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationvan Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Polonsky, W. H., Hessler, D., Ruedy, K. J., & Beck, R. W. (2017) · Diabetes Care · doi:10.2337/dc17-0133 · Cited by 346
Effectiveness of Continuous Glucose Monitoring in a Clinical Care Environment
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2010) · Diabetes Care · doi:10.2337/dc09-1502 · Cited by 313
Mauras, N., Beck, R., Xing, D., Ruedy, K., Buckingham, B., Tansey, M., White, N. H., Weinzimer, S. A., Tamborlane, W., Kollman, C., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1746 · Cited by 204
Choudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118 · cited 1×
“5,6 The benefits of sensor augmentation and integration into CSII therapy, which include reduced HbA1c levels, 7,8 reduced glucose variability, 8–10 greater treatment satisfaction, 11,12 and reduced hypoglycemia 13–16 have also been demonstrated.”
Self-citationTumminia, A., Crimi, S., Sciacca, L., Buscema, M., Frittitta, L., Squatrito, S., Vigneri, R., & Tomaselli, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2557 · Cited by 100
Del Favero, S., Boscari, F., Messori, M., Rabbone, I., Bonfanti, R., Sabbion, A., Iafusco, D., Schiaffini, R., Visentin, R., Calore, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2815 · Cited by 94
Tsalikian, E., Fox, L., Weinzimer, S., Buckingham, B., White, N. H., Beck, R., Kollman, C., Xing, D., Ruedy, K., & Diabetes Research in Children Network (DirecNet) Study Group (2012) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2011.00837.x · Cited by 83
Self-citationContinuous glucose monitoring in patients with type 1 diabetes using insulin injections
Foster, N. C., Miller, K. M., Tamborlane, W. V., Bergenstal, R. M., & Beck, R. W. (2016) · Diabetes Care · doi:10.2337/dc16-0207 · Cited by 76
Evaluation of Pump Discontinuation and Associated Factors in the T1D Exchange Clinic Registry
Wong, J. C., Boyle, C., DiMeglio, L. A., Mastrandrea, L. D., Abel, K.-L., Cengiz, E., Cemeroglu, P. A., Aleppo, G., Largay, J. F., Foster, N. C., et al. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663963 · Cited by 69
Self-citation
Cited by
A clinical guide to advanced diabetes devices and closed-loop systems using the CARES paradigm
Messer, L. H., Berget, C., & Forlenza, G. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0105 · Cited by 100
Freckmann, G., Eichenlaub, M., Waldenmaier, D., Pleus, S., Wehrstedt, S., Haug, C., Witthauer, L., Jendle, J., Hinzmann, R., Thomas, A., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231190941 · Cited by 86
Pleus, S., Ulbrich, S., Zschornack, E., Kamann, S., Haug, C., & Freckmann, G. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0171 · Cited by 47
Pemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Metadata
- Authors
- Slover, R. H., Tryggestad, J. B., DiMeglio, L. A., Fox, L. A., Bode, B. W., Bailey, T. S., Brazg, R., Christiansen, M. P., Sherr, J. L., Tsalikian, E., Kaiserman, K. B., Sullivan, A., Huang, S., Shin, J., Lee, S. W., & Kaufman, F. R.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-09
- Volume
- 20
- Issue
- 9
- Pages
- 576-584
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2888440236
- Cited by
- 31
- References
- 17
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.